Other News
Tysabri
04-16-2010 |
18:33 hs.
Biogen Idec. Inc. announced four new cases of progressive multifocal leukoencephalopathy in patients treated with multiple sclerosis drug, Tysabri (Natalizumab). A total of 46 patients were infected since the drug was re-launched in the market in 2006.
Hepatitis C experimental drug drop off
06-18-2009 |
15:40 hs.
US Biotechnology Andays Pharmaceuticals Inc. announced they will cut 40 percent of its workforce, and at the same time suspended clinical trial of hepatitis C drug.
Formal Launching
06-02-2009 |
15:30 hs.
Biotechnology Cephalon Inc. said they formally launched Nuvigil, their long-lasting version of almost-blockbuster Provigil (Modafinil)
06-01-2009 |
14:29 hs.
Biotechnology Cephalon Inc. said they formally launched Nuvigil, their long-lasting version of almost-blockbuster Provigil (Modafinil)
12-19-2008 |
16:29 hs.
12-17-2008 |
14:15 hs.
12-16-2008 |
15:58 hs.
12-16-2008 |
10:17 hs.
Jazz Pharmaceutical Inc. announced a reduction of 71 employees (or 24 percent of its work force), to lower operating expenses. The company will continue development of JZP 6 and JZP 8.
12-15-2008 |
17:24 hs.
Alzheimer´s treatment
11-13-2008 |
13:11 hs.
11-11-2008 |
16:01 hs.
Tesofensine
11-06-2008 |
12:13 hs.
Although market analysts are saying it is better to pull out now due to regulating agencies´ stance on weight-loss drugs, Denmark´s NeuroSearch A/S is still seeking a partner to help develop and market its obesity pill tesofensine.
First-line treatment for recurring head/neck tumors
10-31-2008 |
11:43 hs.
ImClone System Inc’s Erbitux will receive a priority review by U.S. health regulators to expand its use with chemotherapy as a first-line treatment for patients with recurring head and neck tumors, reported the company.
Zanolimumab
10-08-2008 |
12:51 hs.
10-07-2008 |
11:20 hs.
Progressive multifocal leukoencephalopathy (PML)
09-12-2008 |
12:37 hs.
Biotech Genentech Inc reported revised label and product information for its non-Hodgkin lymphomas (NHL) and rheumatoid arthritis treatment Rituxan when a patient with rheumatoid arthritis prescribed this medication died after contracting progressive multifocal leukoencephalopathy (PML), a rare brain disease.
LAR formulation still on track for filing by 2009
09-05-2008 |
11:36 hs.
Amylin Pharmaceuticals Inc. has again stated there is no proven relationship between its diabetes treatment Byetta, co- marketed with Eli Lilly & Co., and pancreatic side effects. U.S. health authorities reported in August at least six deaths from this illness in patients on Byetta. The company said their long-acting release Byetta LAR remains on track to be filed in 2009. Further details.
08-28-2008 |
10:15 hs.
$ 371 M Dollars Plan
08-22-2008 |
10:27 hs.
U.S. biotech Genentech reported it may spend some $ 371 million dollars for a bonus plan to retain employees concerned about Swiss Roche Holding´s acquisition bid to take over the company. Roche, which owns 56 percent of the company, offered $ 43.7 million dollars for the remaining 44 percent. Genentech rejected the offer on August 13th. Further details.
08-14-2008 |
12:20 hs.
